1265750-07-9

Upstream product

• 105-07-7 4-cyanobenzaldehyde 
• 1097210-25-7 (S)-4-(2-bromo-1-hydroxyethyl)benzonitrile 
• 52695-39-3 4-oxiran-2-ylbenzonitrile 
• 85554-13-8 (±)-4-(2-bromo-1-hydroxyethyl)benzonitrile 
• 1265323-53-2 ethyl (3S)-1-[2-(4-cyanophenyl)-2-oxoethyl]piperidine-3-carboxylate hydrobromide 
• 1265323-51-0 (S)-ethyl 1-((S)-2-(tert-butyldimethylsilyloxy)-2-(4-cyanophenyl)ethyl)piperidine-3-carboxylate 
• 1265681-31-9 C₁₇H₂₀N₂O₃ 
• 1265323-48-5 ethyl (3S)-1-[(2S)-2-(4-cyanophenyl)-2-hydroxyethyl]piperidine-3-carboxylate 
• 179694-33-8 (S)-(+)-2-(4-cyanophenyl)oxirane 
• 20099-89-2 4-Cyanophenacyl bromide 

Downstream Products

• 1265323-52-1 (S)-ethyl 1-((S)-2-(tert-butyldimethylsilyloxy)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylate 

Relevant academic research and scientific papers

Regioselective Epoxide Ring Opening for the Stereospecific Scale-Up Synthesis of BMS-960, A Potent and Selective Isoxazole-Containing S1P1 Receptor Agonist

This article presents a stereospecific scale-up synthesis of (S)-1-((S)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (BMS-960), a potent and selective isoxazole-containing S1P

SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS

Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.